You have 6 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Programmed Cell Death 1 Receptor

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Anti-Programmed Cell Death Protein 1 Immunotherapy in Head and

Recruiting
  • Head and Neck Cancer
  • Strasbourg, France
    Institut de cancérologie Strasbourg Europe
Apr 14, 2022

Fruquintinib Plus PD-1 in Refractory MSS Metastatic Colorectal

Completed
  • Colorectal Cancer
  • Fruquintinib combined with anti-PD-1 antibodies
  • ChangSha, Hunan, China
    Hunan Cancer Hospital
Aug 27, 2023

NSCLC Trial (pembrolizumab, carboplatin, paclitaxel)

Active, not recruiting
Has Results
  • Non-small Cell Lung Cancer
  • pembrolizumab
  • +3 more
  • (no location specified)
Aug 18, 2022

Recurrent/Metastatic Gastric Cancer Trial in Seoul (Nivolumab, Paclitaxel)

Completed
  • Recurrent/Metastatic Gastric Cancer
  • Nivolumab, Paclitaxel
  • Seoul, Korea, Republic of
    Yonsei University Health System, Severance Hospital
Sep 9, 2022

Lung Cancer Trial in Assiut (Observational Study ( Tissue Biopsy ))

Completed
  • Lung Cancer
  • Observational Study ( Tissue Biopsy )
  • Assiut, Egypt
    Assiut University
Oct 18, 2021

Malignant Melanoma Trial (tremelimumab/durvalumab, ipilimumab/nivolumab and nivolumab monotherapy)

Withdrawn
  • Malignant Melanoma
  • tremelimumab/durvalumab, ipilimumab/nivolumab and nivolumab monotherapy
  • (no location specified)
Nov 12, 2021

Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma Trial in Changchun (Rituximab,

Recruiting
  • Peripheral T-Cell Lymphoma, Not Otherwise Specified
  • Angioimmunoblastic T-cell Lymphoma
  • Changchun, Jilin, China
    The First Bethune Hospital of Jilin University
Apr 7, 2023

NSCLC Trial in Marietta, Taichung City, Tainan (Sacituzumab Govitecan, Pembrolizumab)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Sacituzumab Govitecan
  • Pembrolizumab
  • Marietta, Georgia
  • +2 more
Jan 27, 2023

NSCLC Trial (pembrolizumab, carboplatin, paclitaxel)

Active, not recruiting
Has Results
  • Non-small Cell Lung Cancer
  • pembrolizumab
  • +3 more
  • (no location specified)
Aug 18, 2022

Tumors Trial in Worldwide (Dostarlimab)

Recruiting
  • Neoplasms
  • Dostarlimab
  • Birmingham, Alabama
  • +105 more
Nov 17, 2022

Anti-PD-1 Antibody Plus Regorafenib in Refractory Microsatellite

Completed
  • Metastatic Colorectal Adenocarcinoma
  • regorafenib plus anti-PD-1 antibodies
  • Changsha, Hunan, China
    Hunan Cancer hospital
Jul 4, 2023

Large B-cell Lymphoma Trial in Groningen (89Zr-atezolizumab PET-imaging)

Recruiting
  • Large B-cell Lymphoma
  • 89Zr-atezolizumab PET-imaging
  • Groningen, Netherlands
    University Medical Center Groningen
Jul 15, 2022

Liver Diseases, Hepatocellular Carcinoma, Immunotherapy Trial in Guangzhou (bTAE-HAIC, Lenvatinib, Sintilimab)

Not yet recruiting
  • Liver Diseases
  • +4 more
  • bTAE-HAIC
  • +2 more
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Sep 30, 2023

Liver Diseases, Hepatocellular Carcinoma, Immunotherapy Trial in Guanzhou (bTAE-HAIC, Lenvatinib, Camrelizumab)

Not yet recruiting
  • Liver Diseases
  • +4 more
  • bTAE-HAIC
  • +2 more
  • Guanzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Sep 24, 2023

Soluble Programmed Death 1 isDiagnostic Biomarker of ILD in

Not yet recruiting
  • Rheumatoid Arthritis
  • soluble programmed death 1biomarker
  • (no location specified)
Jan 11, 2022

Advanced Solid Tumors Trial in United States (ARRY-382, Pembrolizumab)

Terminated
Has Results
  • Advanced Solid Tumors
  • Los Angeles, California
  • +29 more
May 21, 2022

Healthy Male Subjects Trial in Changsha (sintilimab (after the change), sintilimab (before the change))

Recruiting
  • Healthy Male Subjects
  • sintilimab (after the change)
  • sintilimab (before the change)
  • Changsha, Hunan, China
    Hunan Cancer Hospital
Dec 5, 2022

B-cell Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia Trial in Charleston (Cyclophosphamide injection, Fludarabine

Not yet recruiting
  • B-cell Non Hodgkin Lymphoma
  • Chronic Lymphocytic Leukemia
  • Cyclophosphamide injection
  • +2 more
  • Charleston, South Carolina
    Hollings Cancer Center at Medical University of South Carolina
Jan 18, 2023

Oral Squamous Cell Carcinoma, Neoadjvant Therapy, Anti-PD-1 Trial in Shanghai (Toripalimab (anti-programmed death-1 inhibitor),

Recruiting
  • Oral Squamous Cell Carcinoma
  • +3 more
  • Toripalimab (anti-programmed death-1 inhibitor)
  • +4 more
  • Shanghai, Shanghai, China
    Ninth People's Hospital, Shanghai Jiao Tong University School of
Oct 8, 2022

Lichen Planus Trial in Cairo (Skin Biopsy)

Not yet recruiting
  • Lichen Planus
  • Skin Biopsy
  • Cairo, Egypt
    Cairo University
May 14, 2021

Urothelial Carcinoma Trial in Worldwide (Zilovertamab vedotin)

Recruiting
  • Urothelial Carcinoma
  • Zilovertamab vedotin
  • Cleveland, Ohio
  • +11 more
Jan 25, 2023

Castration-Resistant Prostatic Tumors Trial in Worldwide (Cetrelimab 480 mg, Apalutamide 240 mg)

Completed
  • Castration-Resistant Prostatic Neoplasms
  • Cetrelimab 480 mg
  • Apalutamide 240 mg
  • San Francisco, California
  • +33 more
Feb 24, 2022

Locally Advanced Basal Cell Carcinoma Trial in Philadelphia (biological, procedure, other)

Not yet recruiting
  • Locally Advanced Basal Cell Carcinoma
  • Cemiplimab
  • +3 more
  • Philadelphia, Pennsylvania
    Thomas Jefferson University Hospital
Jun 28, 2023

Tumor Trial in Chuo-Ku, Kashiwa (JNJ-63723283, Erdafitinib)

Completed
  • Neoplasm
  • Chuo-Ku, Japan
  • +1 more
Nov 3, 2022

Lung Cancer, Non-Small Cell Trial in Worldwide (Pembrolizumab, Dostarlimab, GSK4428859A)

Recruiting
  • Lung Cancer, Non-Small Cell
  • Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
  • +14 more
Dec 26, 2022